CytomX Therapeutics Q4 Revenue Expected to Plunge 79%, Analysts Project 9-Cent Loss
CTMX has more than doubled off its 52-week low of $0.4 on elevated volume (2.2× avg).
Summary
Analysts expect CytomX Therapeutics to report a significant decline in fourth-quarter 2025 revenue, forecasting a 79.3% decrease to $7.9 million, alongside a loss of 9 cents per share. These consensus estimates from LSEG data set the stage for the company's upcoming earnings report on March 16. While the projected loss and substantial revenue drop are negative, this news provides traders with the current market expectations, allowing them to assess potential surprises when the actual results are released. The mean earnings estimate has remained unchanged over the last three months, indicating these expectations are already largely priced in. Traders will closely watch the actual Q4 results against these estimates for any material deviations.
At the time of this announcement, CTMX was trading at $4.94 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $825.2M. The 52-week trading range was $0.40 to $6.35. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.